Alnylam Pharmaceuticals (NASDAQ:ALNY) received FDA approval for its drug Vutrisiran (also known as Amvuttra) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). This approval has enhanced Alnylam’s market position, leading to increased competition within this sector against companies like Pfizer and BridgeBio Pharma. Scotiabank has subsequently raised its price target for Alnylam from $300 to $338. Moreover, Alnylam’s Q4 2024 financial results demonstrated significant growth, alongside its ability for product complaint management using Generative AI via Amazon Bedrock. Alnylam has also been making strides in R&D and has clear pipeline goals to boost its financial performance. A notable achievement is its Interim Phase 1 data of Nucresiran showing sustained TTR knockdown at six months following a single dose. In anticipation of expansion into global markets, Alnylam has submitted an application to the European Medicines Agency (EMA) for Vutrisiran. The company's extramural actions included engagement in Stifel 2025 Virtual CNS Forum and the JP Morgan Healthcare Conference.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 22 Mar 2025 13:40:32 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 3
